Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06017609
- Locations
- πΊπΈ
Waco Cardiology Associates - NextStage Clinical Research, Waco, Texas, United States
π§π¬Ambulatory for Specialized Outpatient Medical Care in Cardiology Individual Practice- Dr. Elena Dotcheva EOOD, Burgas, Bulgaria
π§π¬University Multiprofile Hospital for Active Treatment Georgi Stranski, EAD, Pleven, Bulgaria
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT04465877
- Locations
- πΊπΈ
Qps-Mra, Llc, Miami, Florida, United States
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03832738
- Locations
- π¨π¦
Research Toronto, Toronto, Ontario, Canada
π΅π±Dermoklinika - Centrum Medyczne s.c., M. Kierstan, J. Narbutt, A. Lesiak, Lodz, Poland
π΅π±ETG Siedlce, Siedlce, Poland
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Akros Pharma Inc.
- Registration Number
- NCT03789643
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03358290
- Locations
- πΊπΈ
Forest Hills Dermatology Group, Forest Hills, New York, United States
πΊπΈAtlanta Dermatology Vein and Research Center LLC, Alpharetta, Georgia, United States
πΊπΈClinical Research Advantage, Inc., Evansville, Indiana, United States
Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03018509
Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT02919475
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02805244
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02581124
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Akros Pharma Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT02120976
Β© Copyright 2024. All Rights Reserved by MedPath